SHP.L - Shire plc

LSE - LSE Delayed price. Currency in GBp
4,060.50
-27.50 (-0.67%)
As of 11:59AM BST. Market open.
Stock chart is not supported by your current browser
Previous close4,088.00
Open4,100.00
Bid4,059.50 x 51000
Ask4,062.00 x 53800
Day's range4,054.00 - 4,100.00
52-week range2,940.50 - 4,616.14
Volume388,540
Avg. volume4,857,481
Market cap36.822B
Beta1.34
PE ratio (TTM)8.34
EPS (TTM)486.70
Earnings date2 Aug 2018
Forward dividend & yield0.25 (0.63%)
Ex-dividend date2018-03-08
1y target est60.26
  • Nike takes a dive, Spotify surges, Shire up slightly
    Yahoo Finance17 hours ago

    Nike takes a dive, Spotify surges, Shire up slightly

    Nike, Spotify and Shire are the Yahoo Finance charts of the day.

  • GlobeNewswire2 hours ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire5 hours ago

    Shire plc: Large-Scale European Review Suggests Disparity in Symptom Recognition and Standardized Treatment for Metastatic Adenocarcinoma of the Pancreas

    Large-Scale European Review Suggests Disparity in Symptom Recognition and Standardized Treatment for Metastatic Adenocarcinoma of the Pancreas New analyses from the global phase III NAPOLI-1 study, also ...

  • Reuters19 hours ago

    FTSE falls after BoE vote fuels expectations of Aug rate hike

    MILAN (Reuters) - Britain's top share index fell on Thursday as sterling bounced from seven-month lows following a Bank of England policy vote that bolstered expectations of a rate hike in August. As widely ...

  • GlobeNewswire19 hours ago

    Shire Receives U.S. FDA Approval for New State-of-the-Art Plasma Manufacturing Facility Near Covington, Georgia

    June 21, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the United States Food and Drug Administration (FDA) has approved the company`s first submission for its new plasma manufacturing facility near Covington, Georgia for the production of GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI). The Covington facility will add approximately 30% capacity to Shire`s internal plasma manufacturing network once fully operational.

  • Business Wire19 hours ago

    Form 8.3 - SHIRE PLC - Amendment

    LONDON--(BUSINESSWIRE)-- FORM 8.3 - AMENDMENT TO PURCHASES PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the ...

  • Business Wire22 hours ago

    Form 8.3 - Shire PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire23 hours ago

    FORM 8.3 - SHIRE PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • GlobeNewswireyesterday

    Shire Announces FDA Approval for Label Expansion of CINRYZE® for Prevention of Attacks in Pediatric HAE

    Thursday, June 21, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global biotechnology company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for CINRYZE® (C1 esterase inhibitor [human]), making it available to help prevent angioedema attacks in children aged 6 years and older with hereditary angioedema (HAE).

  • Business Wireyesterday

    Form 8.3 - Shire PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire2 days ago

    Form 8.3 - SHIRE PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • GlobeNewswire2 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Business Wire2 days ago

    Form 8.3 - Shire PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire3 days ago

    Form 8.3 - SHIRE PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes